Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care cung cấp cho các bạn kiến thức về ngành y đề tài: Clinical review: Specific aspects of acute renal failure in cancer patients. | Available online http content 10 2 211 Review Clinical review Specific aspects of acute renal failure in cancer patients Michael Darmon Magali Ciroldi Guillaume Thiery Benoit Schlemmer and Elie Azoulay Assistance Publique des Hôpitaux de Paris Saint-Louis University Hospital Medical ICU Paris France Corresponding author Michael Darmon Published 11 April 2006 This article is online at http content 10 2 211 2006 BioMed Central Ltd Critical Care 2006 10 211 doi cc4907 Abstract Acute renal failure ARF in cancer patients is a dreadful complication that causes substantial morbidity and mortality. Moreover ARF may preclude optimal cancer treatment by requiring a decrease in chemotherapy dosage or by contraindicating potentially curative treatment. The pathways leading to ARF in cancer patients are common to the development of ARF in other conditions. However ARF may also develop due to etiologies arising from cancer treatment such as nephrotoxic chemotherapy agents or the disease itself including post-renal obstruction compression or infiltration and metabolic or immunological mechanisms. This article reviews specific renal disease in cancer patients providing a comprehensive overview of the causes of ARF in this setting such as treatment toxicity acute renal failure in the setting of myeloma or bone marrow transplantation. Introduction Acute renal failure ARF is a serious complication of malignancies that causes substantial morbidity and mortality. Among critically ill cancer patients CICPs 12 to 49 experience ARF and 9 to 32 require renal replacement therapy during their intensive care unit ICU stay 1-5 . The risk for ARF seems higher in CICPs than in other critically ill patients 2 6 . In critically ill patients with cancer acute renal dysfunction usually occurs in the context of multiple organ dysfunctions and is associated with mortality rates ranging from 72 to 85 when renal replacement therapy is .
